Agilent's defensive laboratory ecosystem, 65% recurring revenue, Ignite-led margin recovery, and reshoring catalysts support constructive five-year upside despite elevated valuation and Waters-BD competition.
Overview
Agilent is a global analytical and clinical laboratory technology provider with approximately 18,100 employees, a 285,000-workstation installed base, and FY2025 net revenue of $6.95 billion. Its three segments span LDG, AMG, and the recurring-revenue-heavy ACG, which represents approximately 42% of revenue and supports a high-quality business model through consumables, services, software, and workflow integration. **The central investment advantage is customer lock-in:** validated laboratory methods, regulatory requirements, reliable instruments, and proprietary informatics make switching costly and support recurring aftermarket revenue of approximately 65% of consolidated sales. Q3 FY2026 revenue rose 8.1% reported to $1.878 billion, beating the $1.84 billion consensus estimate, while non-GAAP EPS increased 18.2% to $1.62. Non-GAAP operating margin reached 28.3%, although a $20 million tariff refund contributed 110 bps. Management raised FY2026 revenue guidance to $7.49-$7.51 billion and non-GAAP EPS to $6.18-$6.21. Shares closed at $155.16 and traded at 23.10x forward P/E and 23.45x EV/EBITDA, above historical ranges but supported by recurring cash flow, Ignite savings, replacement cycles, reshoring, and acquisitions. Near-term catalysts are guidance delivery, CrossLab momentum, Biocare integration, and continued margin recovery.